Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO ® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both ...
First global Phase III trial to show significant progression-free and overall survival benefits in this setting —— SAFFRON trial results ...
August 2026 Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after ...
Check out METROPOLIS Stock Reports on The Economic Times. Complete detailed Stock Analysis for METROPOLIS, METROPOLIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results